Clinical Trial: Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T

Brief Summary: This study aims to evaluate the efficacy of lenalidomide associated with CHOP as measured by complete response rate at the end of treatment. Approximately 80 patients aged between 60 and 80 years will be included, to have 70 evaluable patients. The treatment consists of two phases of four 3-weeks cycles: induction phase and consolidation phase, for a total treatment duration of 24 weeks. Each cycle will be broken down as follows: chemotherapy will be administered in the hospital on day 1, prednisone is continued for 5 days and lenalidomide is taken for 14 days. Patients will be followed for at least 18 months after inclusion of the last patient.

Detailed Summary:
Sponsor: The Lymphoma Academic Research Organisation

Current Primary Outcome: Complete response rate [ Time Frame: maximum 60 days after last study drug intake ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: The Lymphoma Academic Research Organisation

Dates:
Date Received: January 20, 2012
Date Started: November 2011
Date Completion: March 2020
Last Updated: May 20, 2016
Last Verified: May 2016